<DOC>
	<DOCNO>NCT01191008</DOCNO>
	<brief_summary>The objective Investigation evaluate safety efficacy long-term treatment Xalacom medical practice . Also , occurrence unknown known adverse drug reaction ( ADRs ) subject treated Xalacom monitor survey period , whether additional treatment outcome investigation and/or post-marketing clinical study require future determine .</brief_summary>
	<brief_title>Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension</brief_title>
	<detailed_description>All patient investigator prescribes first Xalacom® register consecutively number subject reach target number order extract patient enrol investigation random .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patients need administer Xalacom® order enrol surveillance . Patients administer Xalacom® .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Xalacom Regulatory post marketing commitment plan safety</keyword>
</DOC>